- Home
- KC vs ZLAB Comparison
KC vs ZLAB Comparison
Compare KC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | ZLAB |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.0B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KC | ZLAB |
|---|---|---|
| Price | $10.81 | $17.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $17.50 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,268,313,014.00 | $441,629,000.00 |
| Revenue This Year | $25.92 | $30.20 |
| Revenue Next Year | $17.44 | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.11 | ★ 24.14 |
| 52 Week Low | $8.87 | $16.82 |
| 52 Week High | $22.26 | $44.34 |
Technical Indicators
Market Signals| Indicator | KC | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 28.16 |
| Support Level | $10.88 | $16.82 |
| Resistance Level | $11.49 | $18.29 |
| Average True Range (ATR) | 0.38 | 0.63 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 3.54 | 19.26 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.